Related references
Note: Only part of the references are listed.Old drugs, new uses: Drug repurposing in hematological malignancies
Vijay P. Kale et al.
SEMINARS IN CANCER BIOLOGY (2021)
Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?
Paolo Gelosa et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Drug repositioning: a brief overview
Jean-Pierre Jourdan et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2020)
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study
Simone Negrini et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2019)
Raynaud's phenomenon-an update on diagnosis, classification and management
John D. Pauling et al.
CLINICAL RHEUMATOLOGY (2019)
Progress in the Mechanism and Clinical Application of Cilostazol
Huilei Zheng et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Recent advances in the workup and management of Raynaud phenomenon
Anna Lis-Swiety
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ (2019)
The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction
Irwin Goldstein et al.
SEXUAL MEDICINE REVIEWS (2019)
Calcium channel blockers for primary and secondary Raynaud's phenomenon
Fadumo Rirash et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
The aspirin story - from willow to wonder drug
Michael J. R. Desborough et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Sarah A. Holstein et al.
DRUGS (2017)
Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients
Simone Negrini et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2016)
Raynaud's Phenomenon
Fredrick M. Wigley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Raynaud's phenomenon and digital ischaemia - pharmacologic approach and alternative treatment options
Birgit Linnemann et al.
VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE (2016)
Raynaud's Phenomenon: A Brief Review of the Underlying Mechanisms
Manal M. Fardoun et al.
FRONTIERS IN PHARMACOLOGY (2016)
Calcium channel blockers for primary Raynaud's phenomenon
Holly Ennis et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)
Post-traumatic Digital Gangrene Associated with Epinephrine Use in Primary Raynaud's Phenomenon: Lesson for the Future
Carlson-Babila Sama
ETHIOPIAN JOURNAL OF HEALTH SCIENCES (2016)
Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Milosz Regulski et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Cilostazol Attenuates Spinal Cord Ischemia-Reperfusion Injury in Rabbits
Yunus Nazli et al.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2015)
Cilostazol induces vasodilation through the activation of Ca2+-activated K+ channels in aortic smooth muscle
Hongliang Li et al.
VASCULAR PHARMACOLOGY (2015)
Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort
Paul J. Nietert et al.
CLINICAL EPIDEMIOLOGY (2015)
Raynaud's phenomenon: From molecular pathogenesis to therapy
Marcella Prete et al.
AUTOIMMUNITY REVIEWS (2014)
Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study
Eun Young Lee et al.
RHEUMATOLOGY (2014)
Current medical and surgical management of Raynaud's syndrome
Gregory J. Landry
JOURNAL OF VASCULAR SURGERY (2013)
Cyclic AMP-Rap1A signaling activates RhoA to induce α2c-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells
Selvi C. Jeyaraj et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
Pharmacological Treatment of Intermittent Claudication Does Not Have a Significant Effect on Gait Impairments During Claudication Pain
Jennifer M. Yentes et al.
JOURNAL OF APPLIED BIOMECHANICS (2012)
Of targets and anti-targets
Alexandra Flemming
NATURE REVIEWS DRUG DISCOVERY (2012)
The pathogenesis, diagnosis and treatment of Raynaud phenomenon
Ariane L. Herrick
NATURE REVIEWS RHEUMATOLOGY (2012)
Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans
Nisha Charkoudian
JOURNAL OF APPLIED PHYSIOLOGY (2010)
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial
Yukito Shinohara et al.
LANCET NEUROLOGY (2010)
Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle α2C-adrenoceptors
A. H. Eid et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Raynaud's phenomenon: Pathogenesis and management
Richard Bakst et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Phosphodiesterase type 5 - Expanding roles in cardiovascular regulation
David A. Kass et al.
CIRCULATION RESEARCH (2007)
The vascular effects of cilostazol
William S. Weintraub
CANADIAN JOURNAL OF CARDIOLOGY (2006)
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis - The Multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis
SU Kwon et al.
STROKE (2005)
Rho kinase mediates cold-induced constriction of cutaneous arteries -: Role of α2C-adrenoceptor translocation
SR Bailey et al.
CIRCULATION RESEARCH (2004)
Effects of cilostazol in patients with Raynaud's syndrome
S Rajagopalan et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction - Meta-analysis of randomised clinical trials
A Agusti et al.
DRUG SAFETY (2003)
Raynaud's phenomenon.
FM Wigley
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Cilostazol (Pletal®):: A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake
YG Liu et al.
CARDIOVASCULAR DRUG REVIEWS (2001)
Cooling evokes redistribution of α2c-adrenoceptors from golgi to plasma membrane in transfected human embryonic kidney 293 cells
SC Jeyaraj et al.
MOLECULAR PHARMACOLOGY (2001)
Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta
T Nakamura et al.
LIFE SCIENCES (2001)
Silent α2C-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries
MA Chotani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2000)
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication
YG Liu et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2000)
Share Paper
